Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Attention Deficit Disorder with Hyperactivity

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Attention Deficit Disorder with Hyperactivity in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abi-Dargham, A; Gelernter, J; Innis, RB; Kegeles, L; Laruelle, M; Martinez, D; van Dyck, CH1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Attention Deficit Disorder with Hyperactivity

ArticleYear
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2001, Volume: 24, Issue:5

    Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Benzamides; Carrier Proteins; Cocaine; Cocaine-Related Disorders; Dopamine; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Genotype; Humans; Iodine Radioisotopes; Membrane Glycoproteins; Membrane Transport Proteins; Minisatellite Repeats; Neostriatum; Nerve Tissue Proteins; Phenotype; Polymorphism, Genetic; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Schizophrenia; Tomography, Emission-Computed, Single-Photon

2001